# A Study of DB-1310 in Advanced/Metastatic Solid Tumors

> **NCT05785741** · PHASE1,PHASE2 · RECRUITING · sponsor: **DualityBio Inc.** · enrollment: 1000 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** DB-1310
- **DRUG:** Trastuzumab
- **DRUG:** Osimertinib
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT05785741
- **Lead sponsor:** DualityBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-17
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05785741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05785741, "A Study of DB-1310 in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05785741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*